Ibogaine vs. Ketamine: An Honest Side-by-Side Comparison

What is the actual difference between ibogaine and ketamine?

Ketamine is a single-mechanism antidepressant given repeatedly in short sessions. Ibogaine is a multi-target compound given once, over 24–36 hours, that acts on opioid receptors as well as the glutamate system — which is why it is the one associated with interrupting opioid withdrawal.

The ibogaine vs. ketamine comparison starts with pharmacology. Ketamine is a dissociative anaesthetic that has been in surgical and emergency use since the 1960s. In psychiatry it works mainly through NMDA receptor antagonism, which rapidly restores synaptic plasticity in prefrontal regions that become underactive in depression, and promotes BDNF. The antidepressant effect is largely pharmacological: it does not depend on the patient having any particular insight during the session. In 2019 the FDA approved esketamine (Spravato), a nasal-spray formulation, for treatment-resistant depression — the first genuinely new antidepressant mechanism approved in decades.

Ibogaine is an alkaloid from the root bark of the Tabernanthe iboga shrub, native to Central Africa — one compound among at least twelve, and not the same thing as the plant (iboga vs ibogaine). Pharmacologically it is unusual: alongside NMDA antagonism it has affinity for κ- and μ-opioid receptors, sigma receptors, and the serotonin and dopamine transporters, and it increases transcription of the neurotrophic factors BDNF and GDNF. That breadth is the reason it behaves differently from any single-target antidepressant, and the reason its main research history is in substance use disorders rather than mood.

The practical consequence is that these are not two versions of the same thing. Ketamine is a course of treatment you keep returning for. Ibogaine is a single event you prepare for, travel for, and then integrate. Read our overview of how ibogaine treatment works if you want the mechanism in more depth.

Which one works for opioid addiction?

Ibogaine. It is the only one of the two with a research history in opioid dependence, and it directly interrupts acute withdrawal. Ketamine may help with cravings and co-occurring depression, but it does not stop withdrawal and is not a detox tool.

This is the clearest distinction on the page, and it is the reason most people who travel for ibogaine travel for ibogaine specifically. The compound’s action at opioid receptors is what allows a single dose to collapse a withdrawal syndrome that would otherwise take days to weeks — and to do it while the psychological work is happening rather than after.

The longest published follow-up comes from New Zealand, where ibogaine treatment is legally available. Noller, Frampton and Yazar-Klosinski followed 14 opioid-dependent patients for twelve months after a single ibogaine treatment (American Journal of Drug and Alcohol Abuse, 2018 · observational, n=14). They reported significant reductions in Addiction Severity Index drug-use scores at twelve months (p = 0.002), significant reductions in depression scores on the BDI-II (p < 0.001), and significant reductions in acute withdrawal symptoms measured immediately after treatment (p = 0.015).

Fourteen patients is a small sample and the study had no control group. It is, nonetheless, one of the few data sets that follows people out a full year — which matters more than raw sample size when the question is whether an effect lasts. If opioids, kratom or 7-OH are the reason you are reading this, our guide to the detox pathway covers what a program actually involves.

Which one works better for depression?

Ketamine, for most people, most of the time. It is legal in the US, FDA-approved in its esketamine form, supported by randomised controlled trials, and you can start next week. Ibogaine’s depression data is real but observational, and it requires international travel.

We say this even though ibogaine is the modality we are best known for, because it is what the evidence supports. Ketamine has the thing ibogaine does not yet have: controlled trials. It is faster to access, cheaper to start, reversible in the sense that you can simply stop, and in the case of Spravato may be partially covered by insurance. For someone whose primary problem is depression and who has not tried a psychedelic-adjacent treatment before, ketamine is the sensible first step.

The honest limitation on ketamine is durability. A single infusion’s antidepressant effect typically lasts days to a few weeks, which is why the standard protocol is a course of roughly six infusions followed by maintenance. Over a year, that maintenance is what drives the real cost. Ibogaine becomes worth discussing when depression has not responded to ketamine or to standard antidepressants, when it sits on top of unprocessed trauma, or when a single-treatment approach is genuinely preferable to an indefinite one.

Which one works better for PTSD and TBI?

Ibogaine has the stronger PTSD signal, from one well-documented study in veterans. Ketamine’s PTSD evidence is thinner and mostly addresses hyperarousal and the depressive component rather than the trauma itself.

The study people are referring to when they mention “the Stanford ibogaine research” is Cherian and colleagues, published in Nature Medicine in 2024 (2024;30(2):373–381). Thirty male Special Operations veterans with predominantly mild traumatic brain injury travelled to a clinic in Mexico for a single magnesium-ibogaine treatment under the MISTIC protocol. Disability, PTSD, depression and anxiety were all measured by clinicians rather than self-report.

If ketamine is the direction you are leaning, our page on ketamine for depression covers what a course actually involves.

At one month the results were large: effect sizes above 2.0 on every clinician-rated psychiatric scale, mean symptom reductions of at least 81%, response rates of at least 93% and remission rates of at least 83%. Neuropsychological testing showed improvements in processing speed and executive function with no decline in any domain. The authors reported no unexpected or serious adverse events.

Those are the numbers you see quoted everywhere. What is quoted far less often is the study’s own framing, so we will state it plainly: this was a prospective observational study with no control group and no placebo. The authors write that controlled clinical trials are needed to validate the findings, and they explicitly acknowledge they cannot rule out that some of the benefit came from expectancy, from international travel, or from the complementary therapies offered on site. Our page on ibogaine for veterans with TBI goes through the study design in full.

What do the two experiences actually feel like?

A ketamine infusion is a mild, dreamlike hour that most people find pleasant. An ibogaine flood dose is a 24–36 hour experience most people describe as the most demanding thing they have ever done — and it cannot be stopped once it has begun.

Ketamine produces a moderate dissociative state: a floating sensation, some visual distortion, a sense of distance from the body. It usually does not surface deep autobiographical material, and its benefit does not depend on doing so. That makes it a reasonable option for someone who is not prepared for, or not well served by, an intense psychological confrontation.

Ibogaine is a different order of experience. The acute phase brings vivid closed-eye imagery that people tend to describe as cinematic and specific to their own life rather than abstract. That gives way to an extended reflective stage often called the life review, in which significant memories and relationships are revisited at length. The residual stage — fatigue, sensitivity, disrupted sleep — can run for another day or more. Most people do not call it enjoyable. Many call it necessary.

The practical point is that the intensity is not incidental to ibogaine; it appears to be part of how it works, and it is also the reason the preparation and the setting matter so much. A 36-hour experience you cannot exit is not something to undertake in a facility you have not properly vetted.

What does each treatment cost?

A complete ibogaine program runs $5,000 to $15,000 depending on length of stay and facility, plus travel — paid once. The low end is negotiated case by case and applies only when no detox is needed and the person is not currently drinking or using. Ketamine is harder to quote: cash-pay IV infusions commonly run $400 to $800 a session with an induction series of about six, but the real number depends on the facility, the location, whether it is IV ketamine or Spravato, and whether you are paying cash or claiming on insurance.

The part of ibogaine vs. ketamine that people usually get wrong is treating ibogaine’s number as large and ketamine’s as small. Over twelve months they converge. Ibogaine’s cost is front-loaded and singular; ketamine’s is spread out and harder to pin down. We are not going to put an annual figure on ketamine, because the honest answer is that it depends on the facility, the location, whether it is IV ketamine or Spravato, and whether you are paying cash or claiming on insurance — and because maintenance is usually tapered rather than continued at the same rate year after year.

That is not an argument that ibogaine is cheaper — it is an argument that the two need to be compared over the same time horizon. It also depends entirely on durability, which is exactly where ibogaine’s evidence is thinnest: the veterans study followed people for one month, and the New Zealand opioid study for twelve. Neither tells you what year three looks like.

For ibogaine, budget realistically for flights, pre-travel labs and an ECG, and travel insurance on top of the program fee. We break the whole thing down in what ibogaine treatment actually costs and what moves the price. Be sceptical of any clinic quoting well below that range — the gap usually shows up as reduced medical staffing or a shorter stay.

Which one is safer?

Ketamine has the longer clinical safety record and a simpler medical work-up. Ibogaine requires a far more thorough screening process — ECG, bloodwork and a full medication review with tapering — and that screening is precisely what a properly run program does before it admits anyone.

Ketamine’s risks in a clinical setting are well characterised and mostly modest: transient dissociation, a temporary rise in blood pressure, and — with heavy long-term or recreational use rather than supervised courses — bladder problems and psychological dependence.

Ibogaine’s screening requirements are more demanding, and the reason is straightforward: the compound interacts with a long list of medications, and a number of common prescriptions have to be tapered and cleared before treatment. That work-up — an ECG, blood panels, a full history and a medication taper plan — is a standard part of admission at any program worth considering, and it is where anything that would make someone a poor candidate gets identified and discussed. In the Stanford veterans study, magnesium was co-administered as an additional precaution and the authors recorded no unexpected or serious adverse events across all thirty participants.

The screening is not a formality to get past. It is the single clearest signal of whether a facility is running a medical program or selling a retreat. If a clinic will take your booking without an ECG and a medication review, that tells you what you need to know. Our provider standard sets out what we require before we will recommend anyone.

Can you do both — and in what order?

Yes, sequentially, and the usual order is ibogaine first for the reset and the trauma work, then ketamine afterwards in the US for ongoing mood support. They are not given together, and any existing ketamine treatment must be disclosed during ibogaine screening.

The two act through different enough mechanisms that using both across a recovery is not inherently contradictory, and for someone with both severe opioid dependence and long-standing depression it can make sense: ibogaine addresses the dependence and the material underneath it, ketamine provides accessible maintenance once you are home and the harder integration work is under way.

The sequencing is not a decision to make alone. Timing, washout periods and any current prescriptions all need to go to the ibogaine program’s medical team before travel — this is one of the specific things the pre-admission medication review exists to catch.

What does the research not show?

There is no completed placebo-controlled trial of ibogaine. Every headline figure quoted about it — including ours — comes from observational studies with small samples and short follow-up. Ketamine’s evidence base is genuinely stronger.

Most ibogaine vs. ketamine comparisons stop before this part. We put it on the page because almost nobody else in this field does, and because you cannot make a good decision from marketing copy. Here is what is actually missing:

• No control group. The Stanford veterans study was prospective and observational. Its authors state directly that controlled trials are needed and that expectancy, travel and on-site complementary therapies cannot be ruled out as contributors.
• Small samples. Thirty veterans in the Nature Medicine study; fourteen patients in the twelve-month New Zealand opioid study. These are pilot-scale data sets.
• Short follow-up. The veterans study measured outcomes at one month. Several participants had already experienced some return of symptoms by that point, which the authors report rather than bury.
• Narrow populations. The veterans cohort was entirely male, mostly white, drawn from elite military units and in above-average physical condition. Whether the findings generalise to a broader or more medically complex population is untested.
• A recorded death in the literature. The New Zealand twelve-month study reports that one enrolled participant died during treatment. Screening and monitoring standards exist because this is a real medical procedure, not a wellness experience, and any program that does not talk to you about that candidly is not being straight with you.

None of this means the results are not real or that the treatment is not worth considering. It means the honest description is “a strong early signal that needs controlled trials”, not “proven”. Anyone telling you otherwise is selling.

How should you actually choose?

Decide ibogaine vs. ketamine by starting with the primary problem. If it is dependence on opioids, kratom or stimulants, ibogaine is the compound with the relevant evidence. If it is depression or anxiety without a dependence component, start with ketamine in the US. If it is trauma sitting underneath both, the question is sequencing, not either/or.

Frequently asked questions

Is ibogaine stronger than ketamine?

In intensity and duration, yes, and it is not close. A ketamine infusion lasts under an hour and produces mild dissociation. An ibogaine flood dose lasts 24–36 hours and produces full visionary states and an extended life review. “Stronger” is not the same as “better”, though — for depression alone, the milder option has the better evidence.

Can ketamine treat opioid addiction?

Not as a detox. Ketamine may reduce cravings and treat co-occurring depression in someone who is opioid dependent, but it does not interrupt acute withdrawal and it is not a substitute for a detox pathway. That distinction is the main reason people travel for ibogaine.

Is ibogaine legal in the United States?

No. Ibogaine is Schedule I in the US. It is legally available for treatment in Mexico, Costa Rica, Portugal and New Zealand among others, which is why treatment involves travel. Ketamine is Schedule III and available in US clinics, with esketamine FDA-approved for treatment-resistant depression since 2019.

How long do the effects last?

Honestly: we do not have long-term data for ibogaine. Published follow-up runs to one month in the veterans study and twelve months in the New Zealand opioid study. Ketamine’s effects per infusion last days to a few weeks, which is why maintenance is standard. Anyone quoting you a number of years is going beyond the evidence.

Do I have to stop my current medications?

For ibogaine, very likely some of them, and it is not optional. A number of common prescriptions — including several psychiatric medications — have to be tapered and cleared before treatment. This is handled during pre-admission screening with the program’s medical team, and it is one of the main reasons the preparation window exists. Never taper on your own.

Sources. Cherian KN, Keynan JN, Anker L, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine 2024;30(2):373–381. doi:10.1038/s41591-023-02705-w (prospective observational, open label, no control group, n=30). · Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse 2018;44(1):37–46. doi:10.1080/00952990.2017.1310218 (observational, n=14).

Clinically reviewed by Christopher Diviaio, LCSW. Psychedelic Connect is a treatment advisory and client advocacy service. We do not provide medical advice, and nothing here is a substitute for assessment by a qualified clinician.